Cargando…

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation

Chronic lymphocytic leukemia (CLL) cells upregulate Bcl-2 proteins within the lymph node (LN) microenvironment. Signaling via B-cell receptor, Toll-like receptors and CD40 collectively reduce sensitivity to the BCL-2 inhibitor venetoclax. Time-limited treatment with venetoclax plus the BTK-inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kielbassa, Karoline, Haselager, Marco V., Bax, Danique J. C., van Driel, Bianca F., Dubois, Julie, Levin, Mark-David, Kersting, Sabina, Svanberg, Rebecka, Niemann, Carsten U., Kater, Arnon P., Eldering, Eric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244160/ https://www.ncbi.nlm.nih.gov/pubmed/37100883 http://dx.doi.org/10.1038/s41375-023-01898-w

Ejemplares similares

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XL
por: Haselager, Marco V., et al.
Publicado: (2023)

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
por: Levin, Mark-David, et al.
Publicado: (2020)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
por: Kater, Arnon, et al.
Publicado: (2023)

In Vitro 3D Spheroid Culture System Displays Sustained T Cell-dependent CLL Proliferation and Survival
por: Haselager, Marco V., et al.
Publicado: (2023)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

P620: GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL
por: Kater, Arnon, et al.
Publicado: (2023)

Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL
por: Haselager, Marco, et al.
Publicado: (2021)

P619: TRACKING DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.
por: Kersting, Sabina, et al.
Publicado: (2023)

Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication
por: Lu, Pin, et al.
Publicado: (2021)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

S144: BTK AND BCL-2 ACTIVITY AT BASELINE PREDICTS MRD STATUS FOR CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH IBRUTINIB + VENETOCLAX IN THE HOVON 141/VISION TRIAL
por: Urban, Aleksandra, et al.
Publicado: (2023)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

Review of Venetoclax in CLL, AML and Multiple Myeloma
por: Lasica, Masa, et al.
Publicado: (2021)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab
por: Seymour, John F., et al.
Publicado: (2022)

Bridging the Knowledge Gap for Older Patients With CLL on Ibrutinib
por: Nakhoda, Shazia, et al.
Publicado: (2023)

P646: VENETOCLAX RETREATMENT AFTER MRD-GUIDED VENETOCLAX +/- IBRUTINIB: THE IMPROVE STUDY COHORT
por: Scarfò, Lydia, et al.
Publicado: (2023)

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
por: Munir, Talha, et al.
Publicado: (2023)

Ibrutinib combinations in CLL therapy: scientific rationale and clinical results
por: Timofeeva, Natalia, et al.
Publicado: (2021)

Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL
por: D’Rozario, James, et al.
Publicado: (2019)

Venetoclax: A Novel Therapeutic Agent for CLL with CNS Involvement
por: Karbhari, Nishika, et al.
Publicado: (2022)

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Hengeveld, Paul, et al.
Publicado: (2023)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy
por: Ujjani, Chaitra, et al.
Publicado: (2020)

Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
por: Davis, Joanne E., et al.
Publicado: (2021)

Which is the top player for the cardiovascular safety? ibrutinib vs. obinutuzumab in CLL
por: Mascolo, Annamaria, et al.
Publicado: (2023)

Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated With Venetoclax and Pembrolizumab
por: Olivieri, Jacopo, et al.
Publicado: (2022)

Scedosporium apiospermum brain abscesses in a patient receiving ibrutinib and venetoclax
por: Figueroa, Rocio, et al.
Publicado: (2020)

Rare but Serious: Ibrutinib Induced Liver Failure
por: Kleijwegt, Fleur S., et al.
Publicado: (2019)

Inhibition of casein kinase 2 sensitizes mantle cell lymphoma to venetoclax through MCL-1 downregulation
por: Thus, Yvonne J., et al.
Publicado: (2022)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study
por: Reda, Gianluigi, et al.
Publicado: (2018)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib
por: Kazianka, L, et al.
Publicado: (2017)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1fq1qnot6eig2m0bi2knqjgses